Exclusive Summary

• Barrier-free market access: The originator's patent has long expired, making this an essential generic drug ready for immediate, patent-risk-free market entry by distribution partners.
• First-line clinical necessity: Included in the WHO Essential Medicines List, it is the gold standard for CMV treatment/prophylaxis, targeting over 150,000 annual transplant recipients and advanced HIV patients globally.
• Differentiated dosage advantage: The 0.25g specification allows for more precise dose titration in pediatric and renal-impaired patients compared to the conventional 0.5g, offering a unique clinical selling point.
• High barrier and high margin: The sterile lyophilized injection formulation poses strict manufacturing barriers; backed by China's API-formulation integrated supply chain, it offers massive cost advantages and high margins for distributors.